FAST NEWS: Sihuan Pharma turns red, but medical aesthetic business improves
The latest: Sihuan Pharmaceutical Holdings Group Ltd. (0460.HK) announced Wednesday it expects to record a loss before tax of no more than 40 million yuan ($5.6 million) from continuing operations in the…
Product Approval Breathes New Life Into Boan Biotech IPO
The biosimilar drug maker was approved to sell its second new product in China last month as it applies to list in Hong KongKey Takeaways:Boan Biotechnology has filed for a…
Lepu ScienTech Revives IPO After Policy Move Brightens Its Prospects
China’s leading supplier of congenital heart disease devices made its third filing earlier this month for a Hong Kong IPO Key Takeaways: After taking its Lepu Biopharma unit public in…
RELATED ARTICLES
-
Xuanzhu Biopharm set for spin-off in Hong Kong IPO
0460.HK -
Airdoc Tech enjoys healing properties of medical AI rally
2251.HK
-
Earnings blow for CSPC Pharma as the state drives a hard bargain
1093.HK
-
Everest gets boost from core product Nefecon’s inclusion in China’s national health plan
1952.HK
- Innogen Pharma jostles for a slice of the weight-loss market
- Cancer drug maker Genfleet joins Hong Kong IPO influx
